Drug Classification · Questions 1–6
Identify the pharmacological class or categorical label for each drug or receptor. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Which of the following drugs is classified as a mineralocorticoid receptor antagonist?
Correct Answer
C — Spironolactone
Rationale
Spironolactone is a steroidal mineralocorticoid receptor antagonist that competitively blocks aldosterone at the collecting duct principal cell. Furosemide is a loop diuretic. Amiloride is an epithelial sodium channel blocker. Acetazolamide is a carbonic anhydrase inhibitor.
Question 2
Which of the following drugs is classified as an epithelial sodium channel blocker?
Correct Answer
A — Amiloride
Rationale
Amiloride blocks the epithelial sodium channel directly at the luminal surface of the collecting duct and connecting tubule, reducing sodium entry independent of aldosterone levels. Spironolactone is a mineralocorticoid receptor antagonist. Furosemide is a loop diuretic. Mannitol is an osmotic diuretic.
Question 3
Which of the following drugs is classified as a vasopressin type 2 receptor antagonist?
Correct Answer
D — Tolvaptan
Rationale
Tolvaptan is a selective oral vasopressin type 2 receptor antagonist — a member of the vaptan class. It blocks vasopressin-mediated aquaporin-2 insertion in collecting duct principal cells, producing electrolyte-free water excretion. Spironolactone is a mineralocorticoid receptor antagonist. Acetazolamide is a carbonic anhydrase inhibitor. Furosemide is a loop diuretic.
Question 4
Which of the following drugs is classified as a carbonic anhydrase inhibitor?
Correct Answer
B — Acetazolamide
Rationale
Acetazolamide inhibits carbonic anhydrase in the proximal convoluted tubule, impairing bicarbonate reabsorption and producing a bicarbonate diuresis with metabolic acidosis. Torsemide is a loop diuretic. Triamterene is an epithelial sodium channel blocker (potassium-sparing diuretic). Chlorthalidone is a thiazide-type diuretic.
Question 5
Which of the following drugs is classified as an osmotic diuretic?
Correct Answer
A — Mannitol
Rationale
Mannitol is a six-carbon sugar alcohol classified as an osmotic diuretic. It is freely filtered at the glomerulus and neither reabsorbed nor secreted, retaining water osmotically in the tubular lumen. Spironolactone is a mineralocorticoid receptor antagonist. Tolvaptan is a vasopressin type 2 receptor antagonist. Furosemide is a loop diuretic.
Question 6
Which of the following correctly classifies finerenone among the mineralocorticoid receptor antagonists?
Correct Answer
C — Nonsteroidal mineralocorticoid receptor antagonist
Rationale
Finerenone is classified as a nonsteroidal mineralocorticoid receptor antagonist, distinguishing it from spironolactone and eplerenone, which are steroidal agents. Its nonsteroidal structure provides greater receptor selectivity and a distinct tissue distribution profile concentrating in cardiac and renal tissue. Spironolactone (steroidal, high androgen affinity) and eplerenone (steroidal, low androgen affinity) are the other two members of the class.
Core Pharmacology · Questions 7–14
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 7
A man taking spironolactone for heart failure develops breast tenderness and gynecomastia. Which of the following best explains the mechanism of this adverse effect?
Correct Answer
B — Spironolactone and its active metabolite bind androgen and progesterone receptors, producing endocrine effects beyond mineralocorticoid blockade
Rationale
Spironolactone's limited receptor selectivity is the mechanism of its endocrine adverse effects. Its active metabolite canrenone and the parent compound bind androgen and progesterone receptors in addition to the mineralocorticoid receptor, causing gynecomastia and breast tenderness in men and menstrual irregularities in women. These effects are dose-dependent and represent the primary reason for switching to eplerenone or finerenone, which have substantially greater receptor selectivity.
Question 8
A patient on long-term lithium therapy for bipolar disorder develops polyuria and polydipsia resistant to vasopressin administration. His physician adds amiloride to his regimen. Which of the following best explains how amiloride reduces lithium-induced nephrogenic diabetes insipidus?
Correct Answer
D — Amiloride blocks the epithelial sodium channel through which lithium enters principal cells, reducing intracellular lithium accumulation
Rationale
Lithium enters collecting duct principal cells through the epithelial sodium channel and accumulates intracellularly, where it inhibits adenylate cyclase-mediated cyclic adenosine monophosphate generation needed for aquaporin-2 insertion in response to vasopressin. Amiloride blocks this entry channel, reducing intracellular lithium concentration and attenuating the diabetes insipidus without requiring lithium discontinuation. Amiloride is preferred over thiazides in lithium-treated patients because thiazides promote proximal lithium reabsorption and raise plasma lithium levels.
Question 9
A patient given acetazolamide for metabolic alkalosis initially shows increased urine bicarbonate excretion, but the natriuretic effect diminishes over the next several days despite continued dosing. Which of the following best explains why acetazolamide produces a self-limiting diuresis?
Correct Answer
A — The resulting metabolic acidosis progressively reduces the filtered bicarbonate load, eliminating the substrate for continued diuresis
Rationale
Acetazolamide inhibits carbonic anhydrase, preventing bicarbonate reabsorption in the proximal tubule and causing bicarbonate to remain in the tubular lumen and appear in the urine. The resulting metabolic acidosis progressively lowers the serum bicarbonate concentration and therefore the filtered bicarbonate load. As filtered bicarbonate falls, the substrate for the diuretic effect disappears and natriuresis ceases — explaining why acetazolamide produces a self-limiting effect rather than the sustained fluid loss of loop diuretics or thiazides.
Question 10
A patient with severe heart failure and pulmonary edema is given intravenous mannitol for a concurrent cerebral injury. Shortly after infusion begins, his respiratory status worsens. Which of the following best explains why mannitol is contraindicated in heart failure?
Correct Answer
C — Mannitol initially expands intravascular volume by drawing water osmotically from intracellular and interstitial compartments before diuresis begins
Rationale
After intravenous administration, mannitol first creates an osmotic gradient that draws water from the intracellular and interstitial compartments into the plasma, acutely expanding intravascular volume before any diuresis occurs. In a patient with heart failure whose cardiac output cannot accommodate this volume expansion, acute decompensation and worsening pulmonary edema result. The diuresis that follows is too slow to prevent this initial hazardous volume expansion. This biphasic effect — early volume loading followed by delayed diuresis — is the mechanistic basis for mannitol's contraindication in heart failure and pulmonary edema.
Question 11
A patient with heart failure and hyponatremia is treated with tolvaptan. Unlike other diuretics, tolvaptan raises serum sodium without causing urinary sodium loss. Which of the following best explains this property of tolvaptan?
Correct Answer
B — Tolvaptan blocks the vasopressin type 2 receptor, preventing aquaporin-2 insertion and producing electrolyte-free water excretion
Rationale
Tolvaptan blocks the vasopressin type 2 receptor in collecting duct principal cells, preventing the cyclic adenosine monophosphate-mediated insertion of aquaporin-2 water channels into the apical membrane. Without aquaporin-2, water cannot follow the osmotic gradient across the collecting duct epithelium, producing electrolyte-free water excretion — termed aquaresis — without sodium loss. This mechanism differs from all other diuretic classes, which produce natriuresis as their primary effect. The selective removal of free water raises serum sodium concentration and is specifically suited to hyponatremia with inappropriately elevated vasopressin.
Question 12
A patient with refractory volume overload on maximum-dose furosemide is prescribed metolazone as an add-on agent. Which of the following best explains why combining metolazone with a loop diuretic produces additive natriuresis?
Correct Answer
D — Metolazone blocks the sodium-chloride cotransporter in the distal convoluted tubule, preventing compensatory sodium reabsorption at the site where it increases after loop diuretic use
Rationale
Loop diuretics increase sodium delivery to the distal convoluted tubule, where sodium-chloride cotransporter expression compensates over time by upregulating to recapture the excess sodium. Metolazone blocks this compensatory site simultaneously, preventing the distal tubule from recapturing what the loop diuretic spilled. The result is dramatic additive natriuresis from sequential nephron blockade at two distinct tubular sites. This combination requires close electrolyte monitoring within 24 to 48 hours because profound hypokalemia and hypomagnesemia can develop rapidly.
Question 13
A mountaineer traveling to high altitude develops headache, nausea, and fatigue consistent with acute mountain sickness. He begins acetazolamide prophylaxis. Which of the following best explains how acetazolamide prevents altitude sickness?
Correct Answer
A — Acetazolamide induces a metabolic acidosis that restores the ventilatory drive blunted by hypoxia-driven respiratory alkalosis at high altitude
Rationale
At high altitude, hypoxia drives hyperventilation that lowers arterial carbon dioxide and raises arterial pH, producing a respiratory alkalosis that paradoxically blunts the hypoxic ventilatory response and worsens altitude sickness. Acetazolamide inhibits renal carbonic anhydrase, causing bicarbonate wasting and a compensatory metabolic acidosis that restores the pH stimulus for ventilation. This allows more effective acclimatization by sustaining the drive to breathe deeply despite the low ambient oxygen tension.
Question 14
A hospitalized patient with severe hyponatremia is started on tolvaptan. After 12 hours, his serum sodium has risen from 118 to 130 mEq/L. Which of the following best explains why the rate of sodium correction with tolvaptan must be carefully monitored?
Correct Answer
C — Correction exceeding 10 to 12 mEq/L per 24 hours risks osmotic demyelination syndrome from rapid osmolality shifts in a brain adapted to chronic hyponatremia
Rationale
In chronic hyponatremia, the brain adapts by extruding intracellular osmoles to protect cell volume in the low-sodium environment. Rapid sodium correction exposes these osmole-depleted brain cells to a sharply rising extracellular osmolality before they can restore their intracellular solutes, drawing water out of myelin-rich neurons and disrupting myelin sheaths. The resulting osmotic demyelination syndrome — also called central pontine myelinolysis — causes dysarthria, dysphagia, quadriplegia, and potentially locked-in syndrome, and is largely irreversible. The rate limit of 10 to 12 mEq/L per 24 hours prevents this complication.
Clinical Correlations · Questions 15–18
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 15
A 67-year-old man with acute decompensated heart failure is receiving intravenous furosemide. His serum bicarbonate is 34 mEq/L and arterial pH is 7.52. His physician adds acetazolamide to his regimen. Which of the following best explains the mechanism by which acetazolamide corrects this acid-base disorder?
Correct Answer
D — Acetazolamide inhibits carbonic anhydrase in the proximal tubule, impairing bicarbonate reabsorption and promoting its excretion in the urine
Rationale
The metabolic alkalosis in this patient results from loop diuretic-induced bicarbonate retention. Acetazolamide corrects this by inhibiting carbonic anhydrase in the proximal convoluted tubule, which impairs the sodium-hydrogen exchanger-driven reclamation of bicarbonate. Bicarbonate remains in the tubular lumen and is excreted in the urine, directly lowering serum bicarbonate and correcting the alkalosis. In volume-overloaded patients who cannot receive saline to correct their alkalosis, acetazolamide provides targeted bicarbonate excretion without adding volume.
Question 16
A 54-year-old woman is admitted with a serum sodium of 122 mEq/L. She has no signs of volume depletion or edema. Laboratory evaluation is consistent with syndrome of inappropriate antidiuretic hormone secretion. Her urine osmolality is 620 mOsm/kg despite a serum osmolality of 258 mOsm/kg. Her physician selects tolvaptan. Which of the following best explains why tolvaptan is appropriate for this patient?
Correct Answer
B — Tolvaptan blocks the vasopressin type 2 receptor, preventing aquaporin-2 insertion and producing electrolyte-free water excretion that raises serum sodium
Rationale
In syndrome of inappropriate antidiuretic hormone secretion, inappropriately elevated vasopressin drives aquaporin-2 insertion and water retention despite low serum osmolality — explaining the concentrated urine in a hypo-osmolar patient. Tolvaptan competitively blocks the vasopressin type 2 receptor in collecting duct principal cells, preventing aquaporin-2 insertion and producing aquaresis — electrolyte-free water excretion without sodium loss. By selectively removing free water, tolvaptan raises serum sodium. The overcorrection rate limit of 10 to 12 mEq/L per 24 hours must be observed to prevent osmotic demyelination syndrome.
Question 17
A 38-year-old man is brought to the emergency department after a motor vehicle collision with traumatic brain injury and a Glasgow Coma Scale score of 9. Computed tomography shows cerebral edema with midline shift. Intravenous mannitol is administered. Which of the following best explains the mechanism by which mannitol reduces cerebral edema?
Correct Answer
A — Mannitol creates an osmotic gradient between the plasma and brain tissue, drawing water out of the cerebral interstitium across the intact blood-brain barrier
Rationale
Mannitol is freely filtered at the glomerulus and does not cross the intact blood-brain barrier. After intravenous infusion, it raises plasma osmolality, creating an osmotic gradient that draws water from the cerebral interstitium into the bloodstream. This reduces cerebral edema within 15 to 30 minutes of infusion. The effect is temporary and requires repeated dosing with serum osmolality monitoring. Mannitol is contraindicated when the blood-brain barrier is disrupted, because it would then enter brain tissue and paradoxically worsen cerebral edema by creating an osmotic gradient that draws water into rather than out of the brain.
Question 18
A 48-year-old male renal transplant recipient on spironolactone for resistant hypertension develops painful gynecomastia. His nephrologist switches him to a different mineralocorticoid receptor antagonist. Which of the following best explains why the replacement drug causes less gynecomastia than spironolactone?
Correct Answer
C — The replacement drug has substantially lower affinity for androgen and progesterone receptors than spironolactone, reducing the off-target endocrine effects
Rationale
Spironolactone causes gynecomastia because it and its active metabolite canrenone bind androgen and progesterone receptors in addition to the mineralocorticoid receptor. Eplerenone has approximately 40-fold lower affinity for androgen and progesterone receptors than spironolactone, substantially reducing the endocrine adverse effects while maintaining mineralocorticoid receptor blockade. This receptor selectivity difference is the primary pharmacological basis for switching from spironolactone to eplerenone in patients who cannot tolerate the endocrine effects.